123 related articles for article (PubMed ID: 19762338)
1. Stability in community-acquired pneumonia: one step forward with markers?
Menéndez R; Martinez R; Reyes S; Mensa J; Polverino E; Filella X; Esquinas C; Martinez A; Ramirez P; Torres A
Thorax; 2009 Nov; 64(11):987-92. PubMed ID: 19762338
[TBL] [Abstract][Full Text] [Related]
2. Markers of treatment failure in hospitalised community acquired pneumonia.
Menéndez R; Cavalcanti M; Reyes S; Mensa J; Martinez R; Marcos MA; Filella X; Niederman M; Torres A
Thorax; 2008 May; 63(5):447-52. PubMed ID: 18245147
[TBL] [Abstract][Full Text] [Related]
3. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes.
Krüger S; Ewig S; Marre R; Papassotiriou J; Richter K; von Baum H; Suttorp N; Welte T;
Eur Respir J; 2008 Feb; 31(2):349-55. PubMed ID: 17959641
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia.
Menéndez R; Martínez R; Reyes S; Mensa J; Filella X; Marcos MA; Martínez A; Esquinas C; Ramirez P; Torres A
Thorax; 2009 Jul; 64(7):587-91. PubMed ID: 19131448
[TBL] [Abstract][Full Text] [Related]
5. Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia.
Zhydkov A; Christ-Crain M; Thomann R; Hoess C; Henzen C; Werner Z; Mueller B; Schuetz P;
Clin Chem Lab Med; 2015 Mar; 53(4):559-66. PubMed ID: 25014522
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory biomarkers for the diagnosis, monitoring and follow-up of community-acquired pneumonia: clinical evidence and perspectives.
Lippi G; Meschi T; Cervellin G
Eur J Intern Med; 2011 Oct; 22(5):460-5. PubMed ID: 21925053
[TBL] [Abstract][Full Text] [Related]
7. Infection biomarkers in primary care patients with acute respiratory tract infections-comparison of Procalcitonin and C-reactive protein.
Meili M; Kutz A; Briel M; Christ-Crain M; Bucher HC; Mueller B; Schuetz P
BMC Pulm Med; 2016 Mar; 16():43. PubMed ID: 27009083
[TBL] [Abstract][Full Text] [Related]
8. Procalcitonin predicts response to beta-lactam treatment in hospitalized children with community-acquired pneumonia.
Cohen JF; Leis A; Lecarpentier T; Raymond J; Gendrel D; Chalumeau M
PLoS One; 2012; 7(5):e36927. PubMed ID: 22615848
[TBL] [Abstract][Full Text] [Related]
9. Soluble receptor for urokinase plasminogen activator in community-acquired pneumonia in children.
Wrotek A; Pawlik K; Jackowska T
Adv Exp Med Biol; 2013; 788():329-34. PubMed ID: 23835994
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia.
Müller B; Harbarth S; Stolz D; Bingisser R; Mueller C; Leuppi J; Nusbaumer C; Tamm M; Christ-Crain M
BMC Infect Dis; 2007 Mar; 7():10. PubMed ID: 17335562
[TBL] [Abstract][Full Text] [Related]
11. Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia.
Perren A; Cerutti B; Lepori M; Senn V; Capelli B; Duchini F; Domenighetti G
Infection; 2008 Mar; 36(2):163-6. PubMed ID: 18330505
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of C-reactive protein, interleukin-6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients.
Pihusch M; Pihusch R; Fraunberger P; Pihusch V; Andreesen R; Kolb HJ; Holler E
Eur J Haematol; 2006 Feb; 76(2):93-101. PubMed ID: 16405429
[TBL] [Abstract][Full Text] [Related]
13. Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia.
España PP; Capelastegui A; Bilbao A; Diez R; Izquierdo F; Lopez de Goicoetxea MJ; Gamazo J; Medel F; Salgado J; Gorostiaga I; Quintana JM;
Eur J Clin Microbiol Infect Dis; 2012 Dec; 31(12):3397-405. PubMed ID: 23010902
[TBL] [Abstract][Full Text] [Related]
14. Serial procalcitonin levels for predicting prognosis in community-acquired pneumonia.
Ito A; Ishida T; Tachibana H; Ito Y; Takaiwa T
Respirology; 2016 Nov; 21(8):1459-1464. PubMed ID: 27398948
[TBL] [Abstract][Full Text] [Related]
15. Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome.
Arkader R; Troster EJ; Lopes MR; Júnior RR; Carcillo JA; Leone C; Okay TS
Arch Dis Child; 2006 Feb; 91(2):117-20. PubMed ID: 16326799
[TBL] [Abstract][Full Text] [Related]
16. Comparison of procalcitonin and C-reactive protein as markers of sepsis.
Luzzani A; Polati E; Dorizzi R; Rungatscher A; Pavan R; Merlini A
Crit Care Med; 2003 Jun; 31(6):1737-41. PubMed ID: 12794413
[TBL] [Abstract][Full Text] [Related]
17. Procalcitonin kinetics in Legionella pneumophila pneumonia.
de Jager CP; de Wit NC; Weers-Pothoff G; van der Poll T; Wever PC
Clin Microbiol Infect; 2009 Nov; 15(11):1020-5. PubMed ID: 19438643
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ.
Krüger S; Ewig S; Papassotiriou J; Kunde J; Marre R; von Baum H; Suttor N; Welte T;
Respir Res; 2009 Jul; 10(1):65. PubMed ID: 19594893
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic accuracy of C-reactive protein and procalcitonin in suspected community-acquired pneumonia adults visiting emergency department and having a systematic thoracic CT scan.
Le Bel J; Hausfater P; Chenevier-Gobeaux C; Blanc FX; Benjoar M; Ficko C; Ray P; Choquet C; Duval X; Claessens YE;
Crit Care; 2015 Oct; 19():366. PubMed ID: 26472401
[TBL] [Abstract][Full Text] [Related]
20. Procalcitonin and community-acquired pneumonia (CAP) in children.
Giulia B; Luisa A; Concetta S; Bruna LS; Chiara B; Marcello C
Clin Chim Acta; 2015 Dec; 451(Pt B):215-8. PubMed ID: 26434548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
